|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to cash used in operating activities: | |||||
| Depreciation | |||||
| Amortization | |||||
| Amortization of intangibles | |||||
| Loss on revaluation of contingent consideration | |||||
| Non-cash lease expense | |||||
| Stock-based compensation | |||||
| Accretion and short-term investment discount | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses and other current assets | |||||
| Other assets | |||||
| Accounts payable | |||||
| Accrued liabilities | |||||
| Deferred revenue | |||||
| Other liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities | |||||
| Purchase of property and equipment | |||||
| Proceeds from maturity of short-term investments | |||||
| Cash acquired in business acquisitions | |||||
| Net cash (used in) provided by investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from issuance of stock | |||||
| Equity issuance costs | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | |||||
| Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation | |||||
| Cash, cash equivalents, and restricted cash at beginning of period | |||||
| Cash, cash equivalents, and restricted cash at end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Fair value of shares of common stock issued for contingent consideration earnouts | |||||
| Cash and cash equivalents | |||||
| Restricted cash - current | |||||
| Restricted cash | |||||
| Total cash, cash equivalents, and restricted cash | |||||
Loading...